TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Before screening, subjects (or legally authorized representative) must read and sign the IRB approved Informed Consent Form (includes HIPPA and Photo release)~* Subjects must have Fitzpatrick Skin Type I, II or III, and judged by the Investigator to have healthy skin~* Subject's bilateral facial skin must be clear of any confounding irritation, rashes, acne, rosacea, etc. prior to the study~* Subject must be free of systemic retinoids for at least 2 months~* Subject must not be using any topical retinoids, systemic antibiotics, nicotinamide or systemic steroids for 1 month prior to study start~* All other topical medications to face (e.g., steroids, antimicrobials, salicylic acid and benzoyl peroxide) and cosmetics containing retinols, AHA's and bleaching agents such as hydroquinone are to be discontinued at least 2 weeks prior to study initiation~* Subjects will not apply any emollients and cosmetics to the facial area 24 hours prior to study initiation~* Subject must not be planning to become pregnant or nursing before entering the study and during the study period. In addition if using birth control pills, subject must be stabilized for at least 2 months. If subject is of child bearing potential, subject must be using approved method of birth control. Approved methods are birth control pills, implants, patches or spermicide with condoms.~Exclusion Criteria:~* Subjects who are pregnant or nursing~* Subjects who have a grade 1 or more for facial erythema~* Subjects who exhibit any skin condition (i.e., atopic dermatitis, seborrheic dermatitis, and psoriasis) or disease that may require concurrent therapy or may confound the evaluation of drug safety or efficacy~* Subjects who have a history of hypersensitivity to any of the formulation components~* Subjects who have received any experimental drug or used any experimental device 30 days prior to initiation of study therapy~* Subjects who have excessive facial hair that may obstruct or hinder the evaluation of any reactions~* Subjects who use any known photosensitizing agents~* Subjects who presently have skin cancer or actinic keratosis on the face

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Tretinoin & Adapalene-Benzoyl Peroxide (Type: EXPERIMENTAL): Tretinoin and Adapalene-Benzoyl Peroxide facial gels applied once daily in a split face model

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed warm or cold AIHA, defined by symptomatic anemia and positive DAT, in the absence of underlying lymphoproliferative, infectious or neoplastic disease (according to the single Center diagnostic criteria).~* Idiopathic warm or cold AIHA relapsed after first line treatment with oral prednisone.~* Aged \>18 years~* ECOG performance status grade 0, 1 or 2~* No psychiatric illness that precludes understanding concepts of the trial or signing informed consent~* Patients who have provided written informed consent prior to study participation, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.~Exclusion Criteria:~* Cell or humoral immunologic deficit (congenital or acquired)~* Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent~* Active bacterial, viral, or fungal infection requiring systemic therapy HIV or HbsAg positive (with HBV-DNA+) or HCV-Ab positive (with HCV-RNA+) patients~* History of malignancies within 3 years prior to study entry~* Concomitant immunosuppressive or cytotoxic treatment~* Positive pregnancy test. Lactation.~* The presence of associated organ-specific autoimmune diseases do not constitute exclusion criteria. Previous splenectomy does not constitute exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in CHAMPS study~* Participation in a study site willing to participate in the CHAMPIONS10 extension study~* Willingness to enroll in the CHAMPIONS 10 extension~* Willingness to sign informed consent~Exclusion Criteria:~* Discovery of an alternative neurological disorder other than MS as a cause of initial neurological symptoms~* A severe systemic disease with likely mortality within 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Treatment Group (Type: EXPERIMENTAL): Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
- Delayed Treatment Group (Type: ACTIVE_COMPARATOR): Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subject is willing to participate and provide informed consent~* Subject is considered reliable and capable of adhering to the protocol per the judgment of the Investigator~* Subjects in group D must exhibit good organ reserves (within prior 4 weeks) defined as:~  1. Estimated GFR \>35 (formula),~ 2. Platelet count \>65 K/uL,~ 3. Hemoglobin \>10.5 grams/dL~ 4. Total bilirubin \<2.0 mg/dL~* Minimum age 18 years old~* Body mass index (BMI) between 18 and 35 kg/m2~* For cohort D (antiphospholipid antibodies) a. Subjects in group D must have at least one positive antiphospholipid antibody within the last 8 weeks and/or previous confirmed antibodies (2 or more occasions at least 12 weeks apart) : i. Positive lupus anticoagulant ii. anticardiolipin antibody IgM or IgG (\>40U GPL) iii. anti-β2 Glycoprotein1 antibody titer (\>35 units)~Exclusion Criteria~* Pregnant. If female of child-bearing age, negative urinary pregnancy test prior to dosing of quercetin or isoquercetin~* No history of malabsorptive gastrointestinal disorder~* Currently taking aspirin, NSAIDS, warfarin, low-molecular weight heparin or other anticoagulants (such as direct thrombin inhibitors or factor X inhibitors)~  a. Note: Study subjects taking aspirin or NSAIDS, if treating physician concurs, are permitted to enroll if plan to hold for aspirin 10 days or NSAIDS 24 hours prior to dosing of quercetin/isoquercetin~* Prescribed niacin for hyperlipidemia~* Known HIV~* History of sensitivity or intolerance to flavonoids, niacin or ascorbic acid~* May not have uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Quercetin (Type: EXPERIMENTAL): Single dose of quercetin with or without ascorbic acid
- Isoquercetin (Type: ACTIVE_COMPARATOR): Single dose of isoquercetin with or without ascorbic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants between 18 and 24 months old;~* Have not received hepatitis A vaccine before;~* Completed hepatitis B vaccine full immunization schedule;~* Written consent of the guardian of each participant;~Exclusion Criteria of the First Injection:~* History of allergy to vaccine(s), or history of serious adverse reaction to vaccination, such as urticaria, dyspnea, angioneurotic edema, or abdominal pain;~* Autoimmune disease or immunodeficiency;~* Any acute disease that made the conditions of the person unsuitable for vaccination~* Administration of any live attenuated vaccine within 14 days prior to the injection;~* Administration of any subunit vaccine or inactivated vaccine within 7 days prior to the injection;~* Administration of treatment of immunosuppressants (e.g., corticosteroid) within 1 month prior to the injection, or planning for such treatment during this study;~* Body temperature \> 37.0 °C before injection;~* Based on the evaluation of the investigator, there was any other factor that indicating the person was unsuitable for this study;~Exclusion Criteria of the Second Injection:~* Any acute infectious disease, body temperature \> 38.5 °C or acute attacks of chronic diseases within 3 days prior to the second injection;~* Administration of blood product or other investigational drug during this study;~* Occurrence of adverse event at grade 3 or higher and the event was related to the first injection;~* The investigator or the Ethic Committee decided that the subject should be excluded;

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Group 1 (HAV + HAV) (Type: EXPERIMENTAL): Intervention: Inactivated Hepatitis A vaccine (HAV);~Subjects in this group each received 2 doses of inactivated HAV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;
- Group 2 (HAV + HABV) (Type: EXPERIMENTAL): Intervention: Inactivated Hepatitis A vaccine (HAV) and Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 1 dose of inactivated HAV at day 0, and 1 dose of HABV at month 6.~Route of administration: intramuscular injection in deltoid region;
- Group 3 (HABV + HABV) (Type: EXPERIMENTAL): Intervention: Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 2 doses of HABV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardioprotective Effects of GLP-1 and Their Mechanisms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18~* Able to give informed consent~* Elective percutaneous intervention for a single vessel coronary stenosis~* Normal left ventricular function~Exclusion Criteria:~* Severe Co-morbidity~* Type 2 Diabetes Mellitus~* Nicorandil, Sulphonylureas, DPP4 inhibitors, GLP-1 agonists or Insulin use~* Women of child bearing age~* Myocardial infarction in previous three months~* Previous coronary artery bypass grafts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLP-1 (7-36) amide and Glibenclamide (Type: EXPERIMENTAL): Patients will receive 5mg Glibenclamide orally prior to PCI and infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min during PCI
- Glibenclamide alone (Type: EXPERIMENTAL): Glibenclamide 5 mg orally prior to PCI
- GLP-1 (7-36) amide (Type: ACTIVE_COMPARATOR): GLP-1 (7-36) amide
- Saline control (Type: NO_INTERVENTION): 0.9% saline only (no treatment with GLP-1 (7-36) amide or glibenclamide)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 50 years of age or older.~* Diagnosis of early Alzheimer's disease (AD) or mild cognitive impairment (MCI) at minimum. All following criteria must be met:~  * Probable MCI or AD consistent with criteria outlined in (McKhann et al 2011, Petersen et al 2018).~ * Mini Mental State Examination (MMSE) score between 12 and 26.~ * Modified Hachinski Ischemia Scale (MHIS) score of \<= 4~ * Short form Geriatric Depression Scale (GDS) score of \<= 6.~ * PET scan confirming amyloid plaque load using Amyvid (18F-Florbetapir).~* Ability to provide informed consent.~Exclusion Criteria:~* Contraindication for Magnetic Resonance Imaging (MRI).~* Contra-indication history or hypersensitivity to MRI contrast agents (e.g., Dotarem) or microbubbles (e.g., Definity).~* Prior brain surgery, including deep brain stimulation.~* Metallic implants.~* Moderate or severe uncontrolled hypertension (systolic blood pressure \> 140 mmHg).~* Abnormal coagulation profile, e.g. hemophilia A or B.~* Coagulopathy or under anticoagulant therapy.~* History of stroke or cardiovascular disease.~* Active/detectable gingivitis, herpes simplex, hepatitis, tuberculosis, and minor skin or respiratory infections.~* History of seizure disorder.~* History of asthma or allergies to food or medication with significant symptoms in past 3 years.~* Severe brain atrophy.~* Inability to comply with the procedures of the protocol, including follow-up MRI scans.~* Pregnancy or lactation.~* Impaired renal function with estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2 provided by a standard blood test at maximum 2 weeks prior to the ultrasound treatment.~* Active infection/inflammation.~* Acute or chronic hemorrhages, i.e. \> 4 lobar microbleeds, and no siderosis or macrohemorrhages.~* Tumors or space occupying lesions.~* Meningeal enhancements.~* Intracranial hypotension.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Focused ultrasound treatment (Type: EXPERIMENTAL): Neuronavigation-guided focused ultrasound treatment in Alzheimer's disease patients using a single-element transducer in conjunction with Definity Microbubbles (10 μl/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy (initial dose of Angiotensin Receptor Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI), Calcium Channel Blockers (CCB), diuretics or β receptor blocker)~Exclusion Criteria:~* Systolic BP (SBP) level ≥160 mm Hg (≥160 mm Hg in diabetics) or a diastolic BP (DBP) level ≥110 mm Hg (≥100 mm Hg in diabetics) at any time between screening and randomization.~* Patients with type 1 diabetes or poorly controlled type 2 diabetes (glycosylated hemoglobin \>8.0%)~* Patients had evidence of hepatic disease or renal impairment~* Other exclusion criteria included evidence of secondary hypertension or history of cardio-vascular disease.~* Women who were pregnant, nursing, or of childbearing potential and not using acceptable contraception.~Other protocol-defined inclusion/exclusion criteria applied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Valsartan/amlodipine (Type: EXPERIMENTAL): Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
- Nifedipine (Type: ACTIVE_COMPARATOR): Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic evidence of an anaplastic oligodendroglioma. For this study, World Health Organization classification criteria will be used. Central pathology review must take place prior to high-dose therapy but need not occur prior to study entry and induction therapy.~* Pathologic evidence of an anaplastic mixed glioma (i.e. oligoastrocytoma). Again, histopathologic diagnosis will be made using World Health Organization classification criteria. To qualify as a mixed tumor there must be a minimum of 25% oligodendroglial element. Central pathology review must take place prior to high-dose therapy but need not occur in advance of enrollment or induction therapy.~* The diagnostic surgical procedure may have been a complete resection, partial resection, or biopsy.~* Karnofsky performance status \> or equal to 60.~* Granulocyte count \> or equal to 1.5 X 109/L.~* Platelet count \> or equal to 100 X 109/L~* SGOT \< than or equal to 2X upper limit of normal.~* Serum creatinine \< than or equal to 1.5X upper limit of normal~* Bilirubin \< than or equal to 1.5X upper limit of normal~* All patients must sign written informed consent.~Exclusion Criteria:~* Systemic or leptomeningeal metastases (excluding contiguous leptomeninges)~* Prior cranial radiotherapy or systemic chemotherapy~* Other concurrent malignancy (with the exception of cervical carcinoma in situ or basal cell carcinoma of the skin) or serious illness if this would interfere with the prescribed treatment.~* Pregnant or lactating women~* Refusal to use effective contraception

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): temozolomide followed by high dose busulfan and thiotepa

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a Veteran~* Diagnosis of psychotic disorders, schizophrenia, schizoaffective disorder and bipolar illness~* Age 18-70~* Clinically determined to require ongoing treatment with Second Generation Antipsychotics (SGA) such as olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, clozapine~* Experienced weight gain since treatment with SGA's~* Inpatient or outpatient at Long Beach, West Los Angeles, Sepulveda, or Downtown VA~* Competent to sign informed consent~Exclusion Criteria:~* Have recently been diagnosed with schizophrenia (less than 1 year)~* Are pregnant or breast feeding a baby~* Have a medically unstable condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Control group with time-matched study visits
- Lifestyle Balance (Type: ACTIVE_COMPARATOR): Weight management group education and individual counseling
- Usual Care then Lifestyle Balance (Type: OTHER): Participants originally randomized to Usual Care, allowed to change over to Lifestyle Balance at month 6 per their request.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Medication Patch to Treat Children Ages 6-12 With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients 6 to 12 years of age.~* Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by DSM-IV, as manifested in clinical evaluation and confirmed by structured interview.~* Participation in structured morning routine (e.g. school, camp, or other organized activities).~Exclusion Criteria:~* Mental retardation (IQ \<75).~* Subjects with a medical condition, or treatment that will either jeopardize subject safety or affect the scientific merit of the study.~* Subjects with moderate to severe dermatological atopy.~* Subjects with known structural cardiac abnormalities.~* Organic brain disorders.~* Seizure Disorder.~* Subjects with Tourette's syndrome, or a history of psychosis or bipolar disorder.~* Subjects with current comorbid psychopathology that in the investigator's opinion will warrant immediate treatment or will interfere with the safe execution of the protocol (i.e. Anxiety or Major Depressive Disorder rated as moderate on CGI).~* Subjects with a history of intolerable adverse effects or non-response to methylphenidate.~* Pregnant or nursing females.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (MTS) (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete